DrugNews has learned that Bayer has spent $1.4 billion so far to settle approximately 6,760 Yaz lawsuits alleging blood clot injuries like pulmonary embolism or deep vein thrombosis (DVT).
Chicago, IL (PRWEB) August 02, 2013
The birth control safety advocates at DrugNews.net are announcing updated information for women who have taken the contraceptives Yaz or Yasmin. The maker of the drugs recently reported they have spent approximately $1.4 billion to settle cases alleging blood clot injuries*.
DrugNews.net is a resource center that provides patients taking popular prescription drugs with the latest research, safety alerts, recalls and legal news. Visitors can find out if others are experiencing similar side effects and decide if they need legal advice.
The resource center has added warnings from health experts like the British Medical Journal** and FDA*** that birth control pills containing the hormone drospirenone, like Yaz and Yasmin, can increase the risk of blood clots.
Due to the number of patients who’ve filed a Yaz lawsuit alleging side effects, cases were consolidated to a special federal Multi-District Litigation court in Illinois (Yasmin and Yaz (Drospirenone) Marketing, Sales Practices and Products Liability Litigation (MDL No. 2100, Southern District Illinois)). The latest court records show 9,998 cases filed****.
Now, DrugNews has learned that Bayer has spent $1.4 billion so far to settle approximately 6,760 Yaz lawsuits alleging blood clot injuries like pulmonary embolism or deep vein thrombosis (DVT)*.
Anyone affected by blood clots, DVT, stroke or pulmonary embolism after taking Yaz or Yasmin is urged to contact the DrugNews Center or speak with a lawyer about their legal options.
Due to the specialized nature of federal MDL courts, patients should seek a lawyer with experience in defective drug litigation. DrugNews only recommends lawyers who have already settled Yaz lawsuits.
*Bayer Stockholder’s newsletter Pg. 64, 7/31/13; stockholders-newsletter-q2-2013.bayer.com/en/bayer-stockholders-newsletter-2q-2013.pdfx
**BMJ, 10/25/11; ncbi.nlm.nih.gov/pubmed/22027398
***FDA, 10/27/11, http://www.fda.gov/downloads/Drugs/DrugSafety/UCM277384.pdf
****JPML, 7/10/13; jpml.uscourts.gov/sites/jpml/files/Pending_MDL_Dockets_By_District-July-10-2013.pdf